Do analysts prefer SXTP or ZIVO?

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than ZIVO Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is SXTP or ZIVO more profitable?

ZIVO Bioscience has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals -574.91% N/A -131.48% ZIVO Bioscience N/A N/A -2,240.92%

Does the media favor SXTP or ZIVO?

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for ZIVO Bioscience. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat ZIVO Bioscience's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ZIVO Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MAAQ or SXTP?

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Mana Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, MAAQ or SXTP?

Mana Capital Acquisition has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mana Capital Acquisition N/A N/A N/A N/A N/A 60 Degrees Pharmaceuticals $1.41M 3.23 -$7.36M -$8.92 N/A

Is MAAQ or SXTP more profitable?

Mana Capital Acquisition has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets Mana Capital Acquisition N/A N/A N/A 60 Degrees Pharmaceuticals -574.91% N/A -131.48%

Do analysts rate XCUR or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to XCUR or SXTP?

In the previous week, Exicure and Exicure both had 2 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Exicure's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral 60 Degrees Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SXTP or GTBP?

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SXTP or GTBP more profitable?

GT Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals -574.91% N/A -131.48% GT Biopharma N/A N/A -102.03%

Does the media prefer SXTP or GTBP?

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than GT Biopharma. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for GT Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat GT Biopharma's score of -1.32 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

60 Degrees Pharmaceuticals (SXTP) Competitors

$1.71 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.77 +0.06 (+3.33%)

As of 07/2/2026 07:57 PM Eastern

Compare

SXTP vs. ZIVO, MAAQ, TPST, XCUR, and GTBP

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? MarketBeat compares 60 Degrees Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 60 Degrees Pharmaceuticals include ZIVO Bioscience (ZIVO), Mana Capital Acquisition (MAAQ), Tempest Therapeutics (TPST), Exicure (XCUR), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical products" industry.

How does 60 Degrees Pharmaceuticals compare to ZIVO Bioscience?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

ZIVO Bioscience has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
ZIVO Bioscience	N/A	N/A	-2,240.92%

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has a beta of 2.47, indicating that its share price is 147% more volatile than the broader market. Comparatively, ZIVO Bioscience has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

60 Degrees Pharmaceuticals has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A
ZIVO Bioscience	$15.85K	1,309.78	-$7.78M	-$1.71	N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than ZIVO Bioscience. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for ZIVO Bioscience. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat ZIVO Bioscience's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ZIVO Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

60 Degrees Pharmaceuticals beats ZIVO Bioscience on 10 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Mana Capital Acquisition (NASDAQ:MAAQ) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Mana Capital Acquisition has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
Mana Capital Acquisition	N/A	N/A	N/A
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Mana Capital Acquisition has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Mana Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

68.4% of Mana Capital Acquisition shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Mana Capital Acquisition. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Mana Capital Acquisition's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Mana Capital Acquisition	Neutral
60 Degrees Pharmaceuticals	Positive

Summary

60 Degrees Pharmaceuticals beats Mana Capital Acquisition on 7 of the 10 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Tempest Therapeutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, indicating a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

60 Degrees Pharmaceuticals has higher revenue and earnings than Tempest Therapeutics. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

60 Degrees Pharmaceuticals has a beta of 2.47, meaning that its stock price is 147% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.73, meaning that its stock price is 273% less volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Tempest Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Tempest Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Positive
Tempest Therapeutics	Neutral

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tempest Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Summary

60 Degrees Pharmaceuticals beats Tempest Therapeutics on 9 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Exicure?

Exicure (NASDAQ:XCUR) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

42.8% of Exicure shares are held by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Exicure and Exicure both had 2 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Exicure's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
60 Degrees Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure has a beta of 3.61, suggesting that its stock price is 261% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

Exicure has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Exicure has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals. Exicure is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	24.33	-$4.95M	-$1.55	N/A
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Exicure beats 60 Degrees Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to GT Biopharma?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 3.4% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

60 Degrees Pharmaceuticals has higher revenue and earnings than GT Biopharma. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than GT Biopharma. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 1 mentions for GT Biopharma. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat GT Biopharma's score of -1.32 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

60 Degrees Pharmaceuticals currently has a consensus price target of $13.85, indicating a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
GT Biopharma	N/A	N/A	-102.03%

Summary

60 Degrees Pharmaceuticals beats GT Biopharma on 8 of the 14 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTP vs. The Competition

Export

Metric	60 Degrees Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.55M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.19	20.06	28.02	24.70
Price / Sales	3.23	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	-0.29	4.32	10.96	6.46
Net Income	-$7.36M	$64.45M	$3.57B	$337.01M
7 Day Performance	6.21%	2.97%	2.12%	1.69%
1 Month Performance	20.42%	6.83%	5.25%	3.81%
1 Year Performance	-82.15%	29.07%	33.29%	23.90%

60 Degrees Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTP 60 Degrees Pharmaceuticals	3.457 of 5 stars	$1.71 flat	$13.85 +709.9%	-82.2%	$4.55M	$1.41M	N/A	3	Gap Down
ZIVO ZIVO Bioscience	N/A	$4.32 +0.4%	N/A	-58.3%	$17.94M	$15.85K	N/A	10	News Coverage Gap Down
MAAQ Mana Capital Acquisition	N/A	$2.20 +11.7%	N/A	-47.6%	$17.88M	N/A	N/A	1	High Trading Volume
TPST Tempest Therapeutics	1.2397 of 5 stars	$1.16 -7.6%	N/A	-84.7%	$17.18M	N/A	N/A	20	Positive News Short Interest Decrease
XCUR Exicure	0.648 of 5 stars	$2.69 -1.5%	N/A	-70.3%	$17.15M	N/A	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. ZIVO, MAAQ, TPST, XCUR, and GTBP

How does 60 Degrees Pharmaceuticals compare to ZIVO Bioscience?

Summary

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Summary

How does 60 Degrees Pharmaceuticals compare to Tempest Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to Exicure?

Summary

How does 60 Degrees Pharmaceuticals compare to GT Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. ZIVO, MAAQ, TPST, XCUR, and GTBP

How does 60 Degrees Pharmaceuticals compare to ZIVO Bioscience?

Is SXTP or ZIVO more profitable?

Do institutionals & insiders have more ownership in SXTP or ZIVO?

Which has more volatility & risk, SXTP or ZIVO?

Do analysts prefer SXTP or ZIVO?

Which has higher valuation & earnings, SXTP or ZIVO?

Does the media favor SXTP or ZIVO?

Summary

How does 60 Degrees Pharmaceuticals compare to Mana Capital Acquisition?

Is MAAQ or SXTP more profitable?

Which has better earnings & valuation, MAAQ or SXTP?

Do analysts recommend MAAQ or SXTP?

Do institutionals and insiders believe in MAAQ or SXTP?

Does the media prefer MAAQ or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Tempest Therapeutics?

Do analysts prefer SXTP or TPST?

Which has better valuation & earnings, SXTP or TPST?

Which has more volatility and risk, SXTP or TPST?

Does the media prefer SXTP or TPST?

Do insiders and institutionals have more ownership in SXTP or TPST?

Is SXTP or TPST more profitable?

Summary

How does 60 Degrees Pharmaceuticals compare to Exicure?

Do institutionals and insiders have more ownership in XCUR or SXTP?

Does the media refer more to XCUR or SXTP?

Which has more risk and volatility, XCUR or SXTP?

Is XCUR or SXTP more profitable?

Which has better earnings & valuation, XCUR or SXTP?

Do analysts rate XCUR or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to GT Biopharma?

Do insiders and institutionals believe in SXTP or GTBP?

Which has higher valuation & earnings, SXTP or GTBP?

Does the media prefer SXTP or GTBP?

Which has more risk & volatility, SXTP or GTBP?

Do analysts prefer SXTP or GTBP?

Is SXTP or GTBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools